Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Breast CancerTriple Negative Breast CancerResidual CancerCirculating Tumor DNA
Interventions
DRUG

Atezolizumab

Atezolizumab is a type of antibody and is administered intravenously.

DRUG

Sacituzumab govitecan

Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously

Trial Locations (7)

19104

RECRUITING

University of Pennsylvania-Abramson Cancer Center, Philadelphia

37232

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

60451

RECRUITING

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox

60462

RECRUITING

University of Chicago Medical Center for Advanced Care Orland Park, Orland Park

60637

RECRUITING

University of Chicago Medical Center, Chicago

94115

NOT_YET_RECRUITING

University of California San Francisco, San Francisco

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Stand Up To Cancer

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT04434040 - Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Biotech Hunter | Biotech Hunter